Authors
Latest:
New Targeted Therapy in Acute Lymphocytic Leukemia: A Review of Blinatumomab in Relapsed/Refractory Acute Lymphocytic LeukemiaAcute lymphoblastic leukemia (ALL) is a relatively rare malignancy in adults, with an estimated 6250 new cases and 1450 deaths expected in the United States in 2015. Although most patients achieve complete remission with conventional combination chemotherapy regimens, at least two-thirds of high-risk patients relapse.2 While overall survival for children has significantly improved in the last 30 years, newly diagnosed adults continue to have a poor 5-year OS rate, approximating 35%, depending on age and risk factors.
Latest:
Challenges With Patient Selection for Extended Adjuvant Endocrine Therapy in Breast CancerCynthia X. Ma, MD, PhD discusses the challenges with understanding treatment duration for adjuvant endocrine therapy in patients with breast cancer.
Latest:
NSCLC: Factors in Selecting 2L Therapy After Progression on 1L ALK TKIExpert perspectives on factors that aid in the selection of optimal therapy for patients with relapsed/refractory ALK+ non–small cell lung cancer.
Latest:
Immune Checkpoint Inhibitors Show Promise in Glioblastoma TreatmentAn emerging class of immune checkpoint blockade drugs has produced impressive benefits for patients in many solid tumor types. The class' success hints that these drugs ay be successful against central nervous system tumors as well, including glioblastoma.
Latest:
Dr. Danae Delivanis on Pembrolizumab and Nivolumab in Metastatic MelanomaDanae Delivanis, MD, endocrinologist, Mayo Clinic, on the use of pembrolizumab and nivolumab in the treatment of metastatic melanoma.
Latest:
Is It Time to Bring Back the French American British Classification System?Learning more about monocytic resistance to venetoclax is a new direction toward improving outcomes for patients with acute myeloid leukemia.
Latest:
Roundtable Discussion: Catenacci Compares Frontline Treatment for Patients With Gastric CancerThe treatment landscape for gastric cancer is evolving. The use of biomarkers and implementation of testing to improve outcome later on in the course of treatment are being more important.
Latest:
Expert Discusses When to Perform PSMA PET Imaging for Metastatic CRPCDaniel J. George, MD, discusses why he considers using prostate-specific membrane antigen imaging early in treatment of patients with castration-resistant prostate cancer.
Latest:
The Challenges of GVHD in Patients with LymphomaDaniel H. Fowler, MD, discusses the challenges of graph-versus-host-disease (GVHD) in patients with high-risk lymphoma.
Latest:
How T-rapa Cells WorkDaniel H. Fowler, MD, senior investigator, Center for Cancer Research, National Cancer Institute, describes how T-rapa cells work.
Latest:
Dr. Daniel Hamstra on the Benefits of Shorter Radiation Therapy Sessions for Prostate Cancer​Daniel Hamstra, MD, PhD, radiation oncologist, Texas Center for Proton Therapy, Texas Oncology, discusses the benefits of shorter radiotherapy treatment sessions for patients with prostate cancer.
Latest:
Overview of 4 FDA Approvals in Acute Myeloid LeukemiaDaniel J. DeAngelo, MD, PhD, associate professor at the Harvard School of Medicine and a member of the Adult Leukemia Program at Dana-Farber Cancer Institute, highlighted the 4 FDA approvals in the last year for the treatment of patients with acute myeloid leukemia.
Latest:
Clinical Pearls for Community Oncologists Treating Prostate CancerDaniel J. George, MD, offers closing thoughts and advice to community oncologists who treat patients with prostate cancer.
Latest:
Dr. Daniel J. Haraf on a Less Toxic Treatment for Patients With Head and Neck CancerHaraf says historically, medical professionals have treated patients with radiation therapy "from their eyebrows to their collarbones." This approach, while effective, has resulted in an abundance of toxicities.
Latest:
How Cabozantinib is Being Used in Practice for Patients With RCCDaniel James George, MD, professor of Medicine, professor in Surgery, Duke University School of Medicine, discusses how cabozantinib (Cabometyx) is currently being used in practice for patients with renal cell carcinoma (RCC).
Latest:
Targeting Oncogenic Driver Mutations for Cancer TherapyThe dependence of cancer cells on the continued activity of specific oncogenes for proliferation and survival can be explored for drug development.
Latest:
TITAN Trial Finds Survival Benefit for Apalutamide in mCSPCDaniel P. Petrylak, MD, discusses the design and results of the TITAN trial of apalutamide in patients with metastatic castration-sensitive prostate cancer.
Latest:
Petrylak Reviews Results From KEYNOTE-921 in mCRPCDaniel P. Petrylak, MD, discusses background and findings from the phase 3 KEYNOTE-921 study of pembrolizumab plus docetaxel vs placebo plus docetaxel in patients with metastatic castration-resistant prostate cancer who had received prior next-generation hormonal agent therapy.
Latest:
Dr. Oh Discusses myPlan Genetic Testing in Patients With Lung CancerDaniel S. Oh, MD, assistant professor of surgery, University of Southern California, Keck School of Medicine, discusses myPlan genetic testing in patients with lung cancer.
Latest:
Phase I Dose-Escalation Results for Marizomib in Newly Diagnosed GlioblastomaDaniela A. Bota, MD, medical director of Neuro-Oncology at University of California Irvine, discusses the findings from a dose-escalation trial of marizomib.
Latest:
Current Options for Frontline Treatment of CLLDanielle Brander, MD, discusses the current treatment landscape in the frontline setting for patients with chronic lymphocytic leukemia.
Latest:
Expert Highlights Changes in the Treatment Landscape of RCCPatients with renal cell carcinoma have seen a change in standard of care as novel therapies and combinations are quickly approved, says Toni K. Choueiri, MD.
Latest:
Acalabrutinib Improves Long-Term PFS in Patients With High-Risk CLLDanielle M. Brander, MD, discusses updated results from the ELEVATE-TN trial of acalabrutinib in patients with chronic lymphocytic leukemia.
Latest:
Safety and Efficacy of Combination Targeted Therapy and RadiotherapyA review of currently published clinical trials examining the combinaiton of radiation therapy with commonly used targeted agents, such as vascular endothelial growth factor inhibitors, endothelial growth factor receptor inhibitors, and inhibitors of the PI3K/Akt/mTOR pathway.
Latest:
FDA Lifts Partial Clinical Hold on Phase 1 Studies of PRS-343 for Solid TumorsThe FDA has lifted a partial clinical hold on the phase 1 clinical trials of PRS-343 for solid tumors.
Latest:
Final KEYNOTE-048 Results With Frontline Pembrolizumab in Recurrent/Metastatic HNSCCDanny Rischin, MD, director, Division of Cancer Medicine, head, Department of Medical Oncology, Peter MacCallum Cancer Centre, discusses results from the protocol-specified final analysis of the phase III KEYNOTE-048 trial of pembrolizumab (Keytruda) as frontline therapy for recurrent/metastatic head and neck squamous cell carcinoma.
Latest:
Findings for Cemiplimab in Advanced or Recurrent Cervical CancerDanny Rischin, MD, MBBS, FRACP, discussed the results from a phase II trial looking at cemiplimab (Libtayo) in patients with advanced or recurrent cervical cancer.
